Stock Traders Buy High Volume of Call Options on KalVista Pharmaceuticals (NASDAQ:KALV)

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) was the recipient of some unusual options trading activity on Friday. Investors purchased 5,072 call options on the company. This represents an increase of approximately 569% compared to the typical volume of 758 call options.

Insider Activity

In other KalVista Pharmaceuticals news, CEO Benjamin L. Palleiko sold 10,034 shares of the business’s stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $15.57, for a total transaction of $156,229.38. Following the sale, the chief executive officer directly owned 442,883 shares in the company, valued at approximately $6,895,688.31. The trade was a 2.22% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Nicole Sweeny sold 3,975 shares of the company’s stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price of $15.57, for a total transaction of $61,890.75. Following the completion of the sale, the insider directly owned 47,003 shares of the company’s stock, valued at approximately $731,836.71. This represents a 7.80% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 248,009 shares of company stock worth $4,213,467 in the last 90 days. 4.30% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On KalVista Pharmaceuticals

Large investors have recently made changes to their positions in the company. Emerald Advisers LLC grew its stake in KalVista Pharmaceuticals by 30.2% during the third quarter. Emerald Advisers LLC now owns 1,351,254 shares of the specialty pharmaceutical company’s stock worth $16,458,000 after buying an additional 313,205 shares during the last quarter. Tudor Investment Corp ET AL acquired a new stake in shares of KalVista Pharmaceuticals during the third quarter worth approximately $24,360,000. Jefferies Financial Group Inc. bought a new position in shares of KalVista Pharmaceuticals in the third quarter valued at approximately $3,494,000. Blue Owl Capital Holdings LP acquired a new position in shares of KalVista Pharmaceuticals in the 3rd quarter worth approximately $1,522,000. Finally, Stonepine Capital Management LLC grew its position in KalVista Pharmaceuticals by 364.0% during the 2nd quarter. Stonepine Capital Management LLC now owns 100,000 shares of the specialty pharmaceutical company’s stock worth $1,130,000 after acquiring an additional 78,450 shares during the last quarter.

Analysts Set New Price Targets

KALV has been the subject of a number of research reports. Stifel Nicolaus increased their price target on KalVista Pharmaceuticals from $39.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday. Needham & Company LLC raised their target price on KalVista Pharmaceuticals from $35.00 to $36.00 and gave the company a “buy” rating in a research note on Wednesday. HC Wainwright lifted their target price on KalVista Pharmaceuticals from $27.00 to $37.00 and gave the stock a “buy” rating in a report on Friday, January 9th. Citizens Jmp dropped their price target on shares of KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating on the stock in a research report on Thursday. Finally, Wall Street Zen upgraded shares of KalVista Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday. Seven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $32.60.

Key Stories Impacting KalVista Pharmaceuticals

Here are the key news stories impacting KalVista Pharmaceuticals this week:

• Positive Sentiment: Unusual bullish options flow: traders bought 5,072 call options (≈569% above the average of 758), suggesting speculative or hedged bullish positioning that can amplify near-term upside interest in the shares.
• Positive Sentiment: Stifel Nicolaus raised its price target to $42 and reiterated a “buy” rating — a large upside vs. the current level that often attracts renewed investor attention and buying. Stifel price target raise
• Positive Sentiment: Needham & Company increased its target to $36 and kept a “buy” rating, reinforcing analyst conviction from multiple firms. Needham target raise
• Positive Sentiment: EKTERLY commercial launch showing strong initial revenue: KalVista reported $49.1M in EKTERLY revenue during an eight-month transition period — a material commercial proof point that supports revenue growth expectations. EKTERLY revenue report
• Positive Sentiment: Stock hit a new 52-week high after analyst upgrades and increased coverage, a technical signal that can attract momentum buyers. 52-week high / analyst upgrade
• Neutral Sentiment: Recent earnings materials (Q1 2025 call summary and transcript) have been published — useful for revisiting guidance and management commentary but the market reaction depends on details and forward guidance. Q1 2025 earnings call summary
• Negative Sentiment: Citizens Jmp trimmed its price target slightly from $29 to $28 (still a “market outperform”), a modest downtick in one analyst’s view that could temper upside expectations if other firms follow. Citizens Jmp target change

KalVista Pharmaceuticals Trading Up 2.0%

Shares of KALV opened at $19.33 on Friday. The business’s 50-day moving average price is $16.04 and its 200 day moving average price is $14.46. The company has a current ratio of 7.22, a quick ratio of 7.21 and a debt-to-equity ratio of 8.18. The stock has a market capitalization of $990.08 million, a P/E ratio of -4.89 and a beta of -0.35. KalVista Pharmaceuticals has a 1-year low of $9.23 and a 1-year high of $19.95.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.